ARMP
Armata Pharmaceuticals Inc
3.50$
+6.3%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 18.0% | 19.2% | 32.8% | – | 10.5% | 30.8% | 76.8% | 16.9% | 31.9% | 38.5% | 57.9% | 23.5% | 33.1% | |
| 82.0% | 80.8% | 67.2% | – | 89.5% | 69.2% | 23.2% | 83.1% | 68.1% | 61.5% | 42.1% | 76.5% | 66.9% | |
| 651.3% | 518.8% | 829.8% | – | 319.0% | 684.2% | 1,105.7% | 294.8% | 502.5% | 559.4% | 774.5% | 302.2% | 461.7% | |
| 292.5% | 208.0% | 329.0% | – | 109.1% | 269.1% | 662.5% | 120.7% | 268.4% | 315.8% | 438.9% | 208.6% | 274.9% | |
| 925.7% | 707.7% | 1,126.0% | – | 417.3% | 922.6% | 1,691.4% | 398.7% | 670.9% | 1,274.0% | 1,155.5% | 487.3% | 774.8% | |
| -843.8% | -626.9% | -1,058.8% | – | -328.2% | -853.4% | -1,668.2% | -315.5% | -670.9% | -1,274.0% | -1,113.4% | -410.8% | -734.2% | |
| 96.0% | 94.9% | 188.4% | – | 98.3% | 265.6% | 733.6% | 175.6% | 375.0% | 445.5% | 704.6% | 264.3% | 385.6% | |
| -2,543.8% | -1,298.9% | -2,590.2% | – | -184.4% | 210.5% | -1,330.1% | -751.3% | -2,301.6% | -11,456.0% | -14,619.3% | 2,953.8% | -3,467.0% | |
| -1,196.5% | 1,163.4% | 28.3% | – | – | -22.2% | – | – | – | – | – | – | – | |
| -2,543.8% | -1,298.9% | -2,590.2% | – | -184.4% | 210.5% | -1,330.1% | -751.3% | -2,301.6% | -11,456.0% | -14,619.3% | 2,953.8% | -3,467.0% | |
| -2,429.7% | -1,184.8% | -2,368.9% | – | -75.5% | 506.9% | -519.8% | -558.8% | -1,894.7% | -10,972.0% | -13,856.8% | 3,241.7% | -3,048.3% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.